Translating Immuno-Oncology Targets into Radioligand Precision Platforms
11:30 am - Wednesday 25th February 2026
- Exploring how integrating antibody engineering with radioligand design enables precise delivery of therapeutic isotopes to immune-relevant tumor environments
- Showcasing how emerging immune-regulatory targets beyond PD-(L)1 offer novel pathways for targeted radioligand modulation
- Analyzing tumor-restricted glycoproteins as highly specific anchors for next-generation theranostic development
New Company for 2026
